Sonoda Yuri, Yamamura Kenichiro, Ishii Kanako, Ohkubo Kazuhiro, Ihara Kenji, Sakai Yasunari, Ohga Shouichi
Kyushu University Graduate School of Medical Sciences, Department of Pediatrics, Fukuoka, Japan
Oita University Faculty of Medicine, Department of Pediatrics, Oita, Japan
J Clin Res Pediatr Endocrinol. 2019 May 28;11(2):207-210. doi: 10.4274/jcrpe.galenos.2018.2018.0169. Epub 2018 Oct 16.
Prostaglandin I (PGI) causes hyperthyroidism, a critical complication in patients with pulmonary arterial hypertension (PAH). However, it remains unknown whether PGI may have unfavorable effects on thyroid function in children with congenital portosystemic venous shunt syndrome (CPSVS). We present a boy with CPSVS who developed PAH at seven years of age. During ongoing PGI therapy, he experienced thyrotoxicosis at 17 years of age. The literature review showed that the reported 12 patients with PAH (median 11 years of age) developed hyperthyroidism during between one and 11 years of PGI treatment. Only one patient survived the acute PAH crisis due to hyperthyroidism. These data provide evidence that prophylactic intervention for hyperthyroidism is indicated for children with CPSVS during PGI treatment.
前列腺素I（PGI）可导致甲状腺功能亢进，这是肺动脉高压（PAH）患者的一种严重并发症。然而，PGI对先天性门体静脉分流综合征（CPSVS）患儿的甲状腺功能是否有不良影响仍不清楚。我们报告一名患有CPSVS的男孩，他在7岁时患上了PAH。在持续的PGI治疗期间，他在17岁时出现了甲状腺毒症。文献综述显示，报告的12例PAH患者（中位年龄11岁）在PGI治疗1至11年期间出现了甲状腺功能亢进。由于甲状腺功能亢进导致的急性PAH危机，只有1例患者存活。这些数据提供了证据，表明在PGI治疗期间，对CPSVS患儿应进行甲状腺功能亢进的预防性干预。
